

Amendments to the Claims:

1. (Currently Amended) A formulation for nasal application comprising:
 - a) at least one sexual hormone drug;
 - b) at least one lipophilic or partly lipophilic carrier, comprising at least one oil in an amount of between 60% and 98% by weight of the formulation; and
 - c) a compound or a mixture of compounds having surface tension decreasing activity[[,]] in amount effective for *in situ* generation of an emulsion upon contact of the formulation with water.
2. (Original) The formulation according to claim 1, wherein the lipophilic carrier comprises an oil.
3. (Previously Presented) The formulation according to claim 2, wherein said oil is a vegetable oil.
4. (Original) The formulation according to claim 3, wherein said oil is castor oil.
5. (Previously Presented) The formulation according to claim 2, wherein the amount of oil comprises between 75% and 95% by weight of the formulation.
6. (Previously Presented) The formulation according to claim 1, wherein component (c) comprises at least one surfactant selected from the group consisting of lecithin, fatty acid ester of polyvalent alcohols, of sorbitanes, of polyoxyethylensorbitans, of polyoxyethylene, of sucrose, of polyglycerol and/or at least one humectant selected from the group consisting of sorbitol, glycerine, polyethylene glycol, and macrogol glycerol fatty acid ester, or a mixture thereof.
7. (Original) The formulation according to claim 6, wherein component (c) comprises an oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides.

8. (Previously Presented) The formulation according to claim 6, wherein component (c) is comprised within the formulation in an amount of from 1 to 20% by weight.

9. (Previously Presented) The formulation according to claim 1, further comprising a viscosity regulating agent.

10. (Original) The formulation according to claim 9, wherein said viscosity regulating agent comprises a thickener or gelling agent selected from the group consisting of cellulose and cellulose derivatives, polysaccharides, carbomers, polyvinyl alcohol, povidone, colloidal silicon dioxide, cetyl alcohols, stearic acid, beeswax, petrolatum, triglycerides and lanolin, or a mixture thereof

11. (Previously Presented) The formulation according to claim 10, wherein said viscosity regulating agent is colloidal silicon dioxide.

12. (Previously Presented) The formulation according to claim 9, wherein the viscosity regulating agent is comprised within the formulation in an amount of from 0.5 to 10% by weight.

13. (Previously Presented) The formulation according to claim 1, wherein the sexual hormone drug is testosterone.

14. (Previously Presented) The formulation according to claim 1, wherein the sexual hormone drug is comprised within the formulation in an amount of from 0.5 to 6% by weight.

15. (Previously Presented) The formulation of claim 5, wherein the amount of oil comprises between 895% and 95% by weight of the formulation.

16. (Previously Presented) The formulation of claim 8, wherein component (c) is comprised within the formulation in an amount of from 1 to 10% by weight.

17. (Previously Presented) The formulation of claim 8, wherein component (c) is comprised within the formulation in an amount of from 1 to 5% by weight.

18. (Previously Presented) The formulation of claim 9, wherein the viscosity regulating agent is comprised within the formulation in an amount of from 0.5% to 5% by weight.

19. (Previously Presented) The formulation of claim 9, wherein the viscosity regulating agent is comprised within the formulation in an amount of from 1 to 3% by weight.

20. (Previously Presented) The formulation of claim 1, wherein the sexual hormone drug is comprised within the formulation in an amount of from 2 to 4% by weight.

21. (Previously Presented) The formulation of claim 1, wherein the sexual hormone drug is comprised within the formulation in an amount of from 0.5 to 2% by weight.